475 GEN-011–101 (the TiTAN-1 trial): phase 1 study to evaluate the safety, proliferation and persistence of GEN-011, an autologous neoantigen-targeted peripheral T cell therapy in solid tumors

475 GEN-011–101 (the TiTAN-1 trial): phase 1 study to evaluate the safety, proliferation and persistence of GEN-011, an autologous neoantigen-targeted peripheral T cell therapy in solid tumors

Bibliographic Details
Main Authors: Thomas Davis, Jessica Price, Arthur DeCillis, Richard Hernandez, Kevin Mancini, Craig Carey
Format: Article
Language:English
Published: BMJ Publishing Group 2021-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items

Similar Items